logo
explain how to read the page

The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers 1
  • 1
    Morrison, James William
    Born in January 1985
    Individual (6 offsprings)
    Officer
    2021-03-03 ~ now
    OF - Director → CIF 0
    Mr James William Morrison
    Born in January 1985
    Individual (6 offsprings)
    Person with significant control
    2021-03-03 ~ now
    PE - Right to appoint or remove directorsCIF 0
    PE - Ownership of shares – 75% or moreCIF 0
    PE - Ownership of voting rights - 75% or moreCIF 0
parent relation
Company in focus

CY BIOPHARMA LTD

Period: 2023-12-20 ~ now
Company number: 13241873
Registered names
CY BIOPHARMA LTD - now
SKYE BIOPHARMA LTD - 2023-12-20
Standard Industrial Classification
21200 - Manufacture Of Pharmaceutical Preparations
72110 - Research And Experimental Development On Biotechnology
Brief company account
Average Number of Employees
02023-01-01 ~ 2023-12-31
02022-04-01 ~ 2022-12-31
Debtors
Current
1,002,342 GBP2023-12-31
1,903,682 GBP2022-12-31
Cash at bank and in hand
7,497 GBP2023-12-31
33,205 GBP2022-12-31
Current Assets
1,009,839 GBP2023-12-31
1,936,887 GBP2022-12-31
Net Current Assets/Liabilities
999,219 GBP2023-12-31
1,000,014 GBP2022-12-31
Total Assets Less Current Liabilities
999,219 GBP2023-12-31
1,000,014 GBP2022-12-31
Equity
Called up share capital
1,000,000 GBP2023-12-31
1,000,000 GBP2022-12-31
Retained earnings (accumulated losses)
-781 GBP2023-12-31
14 GBP2022-12-31
Equity
999,219 GBP2023-12-31
1,000,014 GBP2022-12-31
Amounts Owed by Group Undertakings
Current
1,000,197 GBP2023-12-31
1,903,682 GBP2022-12-31
Other Debtors
Current
2,000 GBP2023-12-31
Debtors - Deferred Tax Asset
Current
145 GBP2023-12-31
Debtors
Current, Amounts falling due within one year
1,002,342 GBP2023-12-31
1,903,682 GBP2022-12-31
Trade Creditors/Trade Payables
Current
420 GBP2023-12-31
Amounts owed to group undertakings
Current
869,837 GBP2022-12-31
Corporation Tax Payable
Current
4,464 GBP2022-12-31
Accrued Liabilities
Current
10,200 GBP2023-12-31
13,200 GBP2022-12-31
Future Minimum Lease Payments Under Non-cancellable Operating Leases
Amounts falling due within one year
24,000 GBP2023-12-31
Between one and five year
12,000 GBP2023-12-31
All periods
36,000 GBP2023-12-31

  • CY BIOPHARMA LTD
    Info
    SKYE BIOPHARMA LTD - 2023-12-20
    Registered number 13241873
    4th Floor, St. James House, St. James Square, Cheltenham GL50 3PR
    PRIVATE LIMITED COMPANY incorporated on 2021-03-03 (5 years 1 month). The status of the company number is Active.
    The last date of confirmation statement was made at 2025-03-02
    CIF 0
child relation
Offspring entities and appointments 0
  • Not found in our database.

The content of this website is protected by AgonGuard.

© 2022- Polylogarithmic Technology Ltd (Registered in England and Wales No. 14256313). All rights reserved.

Contains public sector information retrieved at 22 March 2026 and licensed under the Open Government Licence v3.0.